Furthest along
2 approved
1 in Phase 3
Drugs
4
in active trials · 5 in all
Trials
13 active
22 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
EGFR inhibitor (third generation) |
ArriVent BioPharma |
Approved in China | Dec 2026Phase 3 trial completes | ||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer and 17 more | ||||
| Open drug page | |||||
— |
Approved in China | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor, Non-small Cell Lung Cancer and 10 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | KRAS P.G12C, Non-small Cell Lung Cancer and 4 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2026Phase 1 trial completes | |||
| Next date | Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Locally Advanced or Metastatic Non-small Cell Lung Cancer | ||||
| Open drug page | |||||
About
- No active trial
- Rifampicin
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev